Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Medici Therapeutics Inc. currently has 6 pending office actions in the Chemistry & Materials technology area. These 6 pending office actions are being reviewed by 6 distinct examiners, which means every active application is being handled by a different official. This lack of examiner overlap suggests that the company must manage 6 unique sets of examiner preferences and technical perspectives simultaneously. For practitioners, this means that the outcome of one case is unlikely to provide a direct procedural advantage for the others.
The workload is distributed across 5 distinct art units, indicating a broad technical range within the company's chemistry-related filings. KASS, BENJAMIN JOSEPH is the busiest examiner, though this role involves only 1 busiest examiner pending action. This confirms that the 6 pending office actions are entirely decentralized, with no single examiner holding a majority of the cases. There is no single official who holds a majority of the company's current workload.
For patent practitioners, the presence of 5 distinct art units and 6 distinct examiners requires a highly individualized approach to each application. There is no opportunity to leverage a single relationship to resolve multiple 6 pending office actions. Success in this portfolio will depend on the ability to tailor arguments to the specific requirements of each of the 5 distinct art units involved. Each of the 6 pending office actions must be addressed as an independent matter with its respective examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (33%) |
| §103 only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KASS, BENJAMIN JOSEPH | 1 | 31.1% | +64.4% |
| WITHERSPOON, SIKARL A | 1 | 86.3% | -20.1% |
| BORTOLI, JONATHAN | 1 | 76.4% | +40.2% |
| ALABI, OYELEYE A | 1 | 83.9% | +23.8% |
| REVERMAN, CHAD ANDREW | 1 | 58.7% | +41.1% |
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681538 | COMPOSITIONS COMPRISING HYDROXYETHYL-CAPPED CATIONIC PEPTOIDS | WITHERSPOON, SIKARL A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18649451 | MICROFLUIDIC APPARATUS AND METHODS OF USE THEREOF | KASS, BENJAMIN JOSEPH | — |
| 18565192 | SYSTEMS AND METHODS TO DETECT PRESENCE OF FLUIDS | BORTOLI, JONATHAN | — |
| 18286851 | APPARATUS WITH DYNAMIC LIGHT SCATTERING ASSEMBLY | ALABI, OYELEYE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17615857 | LIPIDATED CATIONIC PEPTIDE-PEG COMPOSITIONS FOR NUCLEIC ACID DELIVERY | KOMATSU, LI N | 55d |
| 18649451 | MICROFLUIDIC APPARATUS AND METHODS OF USE THEREOF | KASS, BENJAMIN JOSEPH | — |
| 18565192 | SYSTEMS AND METHODS TO DETECT PRESENCE OF FLUIDS | BORTOLI, JONATHAN | — |
| 18286851 | APPARATUS WITH DYNAMIC LIGHT SCATTERING ASSEMBLY | ALABI, OYELEYE A | — |
| 17964185 | APPARATUS WITH DYNAMIC LIGHT SCATTERING ASSEMBLY | REVERMAN, CHAD ANDREW | — |
| Art Unit | Apps |
|---|---|
| 1797 | 2 |
| 1798 | 1 |
| 1692 | 1 |
| 2877 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18649451 | MICROFLUIDIC APPARATUS AND METHODS OF USE THEREOF | KASS, BENJAMIN JOSEPH | 1798 | §102§103 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18681538 | COMPOSITIONS COMPRISING HYDROXYETHYL-CAPPED CATIONIC PEPTOIDS | WITHERSPOON, SIKARL A | 1692 | §102DP | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18565192 | SYSTEMS AND METHODS TO DETECT PRESENCE OF FLUIDS | BORTOLI, JONATHAN | 1797 | §101§102§103 | Non-Final OA | — | Pending | Nov 29, 2023 |
| 18286851 | APPARATUS WITH DYNAMIC LIGHT SCATTERING ASSEMBLY | ALABI, OYELEYE A | 1797 | §101§103 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 17964185 | APPARATUS WITH DYNAMIC LIGHT SCATTERING ASSEMBLY | REVERMAN, CHAD ANDREW | 2877 | §103 | Non-Final OA | — | Pending | Oct 12, 2022 |
| 17615857 | LIPIDATED CATIONIC PEPTIDE-PEG COMPOSITIONS FOR NUCLEIC ACID DELIVERY | KOMATSU, LI N | 1658 | §103 | Final Rejection | 55d | Pending | Dec 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedici Therapeutics Inc. has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Benjamin Joseph Kass has the most, with 1 of Medici Therapeutics Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
